Andrew joined GCMI+T3 Labs in 2009. He has led the site transfer and operational start-up of T3 Labs in a new $20 million world-class facility, re-focused the organization on quality-first service model, built sustainable relationships with Fortune 500 medical device manufacturers, academic and healthcare institutions, and startups alike, established a team of highly-qualified independent consultant-Program Leaders that serve over 150 customers annually, and expanded GCMI and T3 Labs’ service offerings to 13 therapeutic and service-oriented programs.
In addition to leading deal-flow and account management for GCMI+T3 Labs services, GCMI recently launched a MedTech Accelerator for which he is accountable. He is also involved in local and state economic development initiatives for life sciences and healthcare.
Prior to moving to GCMI and T3 Labs, he led corporate development raising over $330 million, built and directed three project management offices, support dozens of global development and product launch programs, provided independent consulting services, and conducted laboratory research for several companies. These companies include Abbott Laboratories/Solvay Pharmaceuticals, Bristol-Myers Squibb/DuPont/Merck, an GA Tech ATDC start-up, and the University of Pennsylvania. He holds an M.B.A in International Business from the Alfred Lerner College of Business and Economics, University of Delaware and a B.S. in Chemistry from Davidson College.